$HQY

Fiore Michael Henry sold $235K of HQY

Fiore Michael Henry (EVP, CHIEF COMMERCIAL OFFICER) sold 2,470 shares of HEALTHEQUITY, INC. (HQY) at $95.00 ($0.23M total) on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fiore Michael Henry
Published Jul 7, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
high confidence
Mentioned
$HQY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The disclosed open-market sale is pre-arranged under a Rule 10b5-1 plan, reducing the likelihood of a strong negative read-through versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment, but there is no new operational or financial information to drive repricing.

03

What to watch

The filing does not state motives beyond the 10b5-1 plan; without concurrent fundamentals (guidance, contracts, litigation), the trading signal is likely sentiment-only.

Relevance 3/10Novelty 3/10Timing: Filed July 7, 2026 (covers sale dated July 2, 2026).

Background

The article is an SEC Form 4 insider transaction disclosure for HEALTHEQUITY, INC. (HQY).

Company-level read

Ticker impact

$HQYNeutralHigh confidence
Context

SEC Form 4 shows HQY EVP/Chief Commercial Officer Fiore Michael Henry sold 2,470 shares at $95 on a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying earnings, guidance, or operational change.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide regulatory or operational trigger.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still watch for follow-on sales or changes in buying activity.

Key entities

  • HEALTHEQUITY, INC.

    Subject of the Form 4 insider transaction; EVP/Chief Commercial Officer sold shares under a 10b5-1 plan.

  • Fiore Michael Henry

    EVP, Chief Commercial Officer; reported open-market sale of 2,470 shares at $95.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HQYHighAI 8/10

HealthEquity (HQY) Q2 2027 Earnings Call Transcript

HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.

$HQYMed

Why HealthEquity Stock Sank This Week

HealthEquity (HQY) stock fell 8.6% this week despite beating earnings and revenue estimates for Q2. The company reported adjusted EPS of $1.24 on revenue of $350.7M, up 15.7% and 7.6% YoY, respectively. Investors expected stronger guidance, as the company only slightly raised its full-year revenue target and reiterated EPS guidance.